000 01264 a2200349 4500
005 20250518011054.0
264 0 _c20190308
008 201903s 0 0 eng d
022 _a1521-0669
024 7 _a10.1080/08880018.2018.1539149
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aFlores Legarreta, Alejandra
245 0 0 _aAnti TNF-α therapy in patients with relapsed and refractory Langerhans cell histiocytosis: a phase II study.
_h[electronic resource]
260 _bPediatric hematology and oncology
_c
300 _a362-368 p.
_bdigital
500 _aPublication Type: Clinical Trial, Phase II; Journal Article
650 0 4 _aAdolescent
650 0 4 _aAdult
650 0 4 _aChild, Preschool
650 0 4 _aEtanercept
_xadministration & dosage
650 0 4 _aFemale
650 0 4 _aHistiocytosis, Langerhans-Cell
_xdrug therapy
650 0 4 _aHumans
650 0 4 _aInfant
650 0 4 _aMale
650 0 4 _aTumor Necrosis Factor-alpha
_xantagonists & inhibitors
700 1 _aEckstein, Olive
700 1 _aBurke, Thomas M
700 1 _aMcClain, Kenneth L
773 0 _tPediatric hematology and oncology
_gvol. 35
_gno. 5-6
_gp. 362-368
856 4 0 _uhttps://doi.org/10.1080/08880018.2018.1539149
_zAvailable from publisher's website
999 _c29082874
_d29082874